Anne Balloch, Australia
Murdoch Children's Research Institute Infection and ImmunityAuthor Of 4 Presentations
COMPARISON OF A 2+1 AND 3+0 SCHEDULE OF PCV10 IN VIETNAM (ID 1035)
- Beth Temple, Australia
- Paul V. Licciardi, Australia
- Vo Thi Trang Dai, Viet Nam
- Trong Toan Nguyen, Viet Nam
- Doan Y. Uyen, Viet Nam
- Cattram D. Nguyen, Australia
- Thanh V. Phan, Viet Nam
- Hoan Thi Pham, Viet Nam
- Kathryn Bright, Australia
- Rachel A. Marimla, Australia
- Monica L. Nation, Australia
- Belinda D. Ortika, Australia
- Catherine Satzke, Australia
- Heidi Smith-Vaughan, Australia
- Anne Balloch, Australia
- Tran Ngoc Huu, Viet Nam
- Edward K. Mulholland,
IMMUNOGENICITY OF A SINGLE DOSE OF PCV10 GIVEN AT 18 MONTHS OF AGE AND IMPACT ON NASOPHARYNGEAL CARRIAGE IN VIETNAMESE CHILDREN (ID 735)
- Rachel A. Marimla, Australia
- Beth Temple, Australia
- Thi Trang Dai Vo, Viet Nam
- Thanh V. Phan, Viet Nam
- Trong Toan Nguyen, Viet Nam
- Leena Spry, Australia
- Monica L. Nation, Australia
- Belinda D. Ortika, Australia
- Doan Y. Uyen, Viet Nam
- Cattram D. Nguyen, Australia
- Kathryn Bright, Australia
- Anne Balloch, Australia
- Huu T. Ngoc, Viet Nam
- Kim E. Mulholland, Australia
- Catherine Satzke, Australia
- Paul V. Licciardi, Australia
INCREASED PCV10 IMMUNOGENICITY FOLLOWING A TWO-DOSE PRIMARY SERIES SEPARATED BY 4 MONTHS COMPARED WITH 2 MONTHS IN VIETNAMESE INFANTS (ID 963)
- Paul V. Licciardi, Australia
- Beth Temple, Australia
- Dai V. Trang, Australia
- Trong Toan Nguyen, Viet Nam
- Uyen Y. Doan, Viet Nam
- Cattram D. Nguyen, Australia
- Thanh V. Phan, Viet Nam
- Kathryn Bright, Australia
- Rachel A. Marimla, Australia
- Anne Balloch, Australia
- Tran Ngoc Huu, Viet Nam
- Kim E. Mulholland, Australia
IMMUNOGENICITY OF A SINGLE DOSE OF PCV10 OR PCV13 AT 2 MONTHS OF AGE IN VIETNAM (ID 1007)
Abstract
Background
A 1+1 pneumococcal conjugate vaccine (PCV) schedule would increase its affordability for low and middle-income countries. The Vietnam Pneumococcal Trial II includes infants randomised to receive a 1+1 schedule of PCV10 or PCV13 at 2 and 12 months of age. This study measured the immunogenicity of a single dose of either PCV given at 2 months of age.
Methods
Serotype-specific IgG was measured at 3 and 12 months of age in PCV-vaccinated and unvaccinated controls using a WHO ELISA method.
Results
At 3 months, both vaccinated groups had higher antibody levels than controls for 7/10 serotypes (all except 6B, 14, 23F). The PCV10 group had higher antibody levels than the PCV13 group for 5/10 serotypes. Similar results were seen at 12 months, with higher antibody levels for all serotypes in the PCV10 group and 8/10 serotypes (all except 6V, 23F) in the PCV13 group compared with controls and higher antibody levels in the PCV10 than the PCV13 group for 7/10 serotypes.
Conclusions
A single dose of PCV in infancy is immunogenic and likely to provide some direct protection until the time of the booster dose. There may be a difference in the degree of protection offered by different PCVs.